Host- and disease-specific factors affecting steatosis in chronic hepatitis C

Czaja, Albert J.; Carpenter, Herschel A.; Santrach, Paula J.; Moore, S. Breanndan

doi:10.1016/s0168-8278(98)80004-4

Cited by 228 publications

(196 citation statements)

References 38 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…It has also been reported that chronic hepatitis C patients with moderate steatosis have higher necroinflammatory activity and fibrosis than those with mild steatosis. 21 Recently, it has been shown that steatosis is an independent risk factor associated with fibrosis. 15 A correlation between fibrosis and steatosis has also been shown using a statistical model.…”

Section: Discussionmentioning

confidence: 99%

Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral Obesity

et al. 2001

View full text Add to dashboard Cite

The role of steatosis in the progression of liver damage in chronic hepatitis C (CHC) was studied. Enrolled were 180 consecutive liver biopsy-proven CHC patients and 41 additional subjects with a known duration of infection. We evaluated the histological activity index (HAI), grade of fibrosis and steatosis, body mass index (BMI; kg/m 2 ), distribution of body fat, HCV genotype, and levels of HCV RNA. Eighty six (48%) patients showed steatosis, and a higher prevalence was observed in genotype 3a infection (P < .01). A correlation between the grade of steatosis and fibrosis was observed (P < .001). Fibrosis was also associated with age (P < .001). After adjusting for age, the association between steatosis and fibrosis remained significant. The grade of steatosis also correlated with the HAI (P < .007) with a significant increase in periportal necrosis. No relation was found between steatosis and age, gender, iron storage, or levels of HCV RNA. Patients with a high grade of steatosis (>30%) showed higher serum levels of ␥-GT and ALT (P < .001). Overall, steatosis was not significantly associated to BMI. Analysis by single genotype showed a significant association between the grade of steatosis and BMI in type 1 infection r ‫؍‬ .689; P < .001) and with levels of HCV RNA in type 3a infection r ‫؍‬ .786; P < .001). Visceral fat distribution rather than BMI proved to be associated with steatosis (P < .001). Data obtained from patients with a known date of infection confirmed that steatosis grades 3-4 were associated with a higher annual rate of fibrosis progression, and showed that alcohol and steatosis act together in increasing fibrosis (P < .05). Our data indicate that steatosis is an important cofactor in increasing liver necroinflammatory activity and in accelerating fibrosis in CHC. Visceral obesity and genotype 3a play a role in the development of steatosis. (HEPATOLOGY 2001;33: 1358-1364

show abstract

Section: Discussionmentioning

confidence: 99%

Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral Obesity

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Many studies have now demonstrated a significant relationship between steatosis and hepatic fibrosis (Table 1), [9][10][11][12][13][14][15][16][17][18][19] although most did not adjust for other metabolic risk factors such as obesity, diabetes, or insulin resistance. 18 Adinolfi and colleagues 12 found an increased yearly rate of fibrosis progression in their patients with higher grades of steatosis, and we showed a similar relationship in our patients with chronic HCV (Fig.…”

Section: Steatosis Influences the Progression Of Fibrosis In Chronic Hcvmentioning

confidence: 99%

“…8 The development of cirrhosis in patients with HCV may be associated with regression of steatosis, 21 as has previously been documented in non-alcoholic steatohepatitis (NASH). 22,23 The mechanisms leading to a reduction in steatosis in the liver with cirrhosis remain Mihm et al 99 Yes Ratziu et al 18 Yes Fartoux et al 19 Yes Czaja et al 9 Yes Yes Yes Hourigan et al 10,11 Yes Yes Yes Adinolfi et al 12 Yes Yes Yes Yes Westin et al 13 Yes Weak Yes Yes Castera et al 14 Yes Yes Monto et al 15 Yes Yes Yes Kumar et al 100 Yes Camps et al 101 Yes (BMI) Kaserer et al 102 Yes Bressler et al 60 Yes (BMI) Rubbia-Brandt et al 28 Yes Yes Poynard et al 16 Yes Yes Yes Yes Yes Patton et al 17 Yes Yes Yes Yes Yes Nair et al 70 No* Marrero et al 103 Yes Ohata et al 74 Yes *Steatosis was a risk for HCC in alcoholic and cryptogenic cirrhosis only. Abbreviation: BMI, body mass index.…”

Section: Steatosis Influences the Progression Of Fibrosis In Chronic Hcvmentioning

confidence: 99%

Steatosis: Co-factor in Other Liver Diseases *

2005

View full text Add to dashboard Cite

The prevalence of fatty liver is rising in association with the global increase in obesity and type 2 diabetes. In the past, simple steatosis was regarded as benign, but the presence of another liver disease may provide a synergistic combination of steatosis, cellular adaptation, and oxidative damage that aggravates liver injury. In this review, a major focus is on the role of steatosis as a co-factor in chronic hepatitis C (HCV), where the mechanisms promoting fibrosis and the effect of weight reduction in minimizing liver injury have been most widely studied. Steatosis, obesity, and associated metabolic factors may also modulate the response to alcohol-and drug-induced liver disease and may be risk factors for the development of hepatocellular cancer. The pathogenesis of injury in obesity-related fatty liver disease involves a number of pathways, which are currently under investigation. Enhanced oxidative stress, increased susceptibility to apoptosis, and a dysregulated response to cellular injury have been implicated, and other components of the metabolic syndrome such as hyperinsulinemia and hyperglycemia are likely to have a role. Fibrosis also may be increased as a by-product of altered hepatocyte regeneration and activation of bipotential hepatic progenitor cells. In conclusion, active management of obesity and a reduction in steatosis may improve liver injury and decrease the progression of fibrosis. (HEPATOLOGY 2005;42:5-13.)

show abstract

“…In past, chronic hepatitis C has frequently associated with hepatosteatosis, and it was suggested that hepatosteatosis occured under the effect of Hepatitis C virus [2]. In another study, the patients with chronic hepatitis B and C was compared resulting an increased frequency of steatosis in patients with chronic hepatitis C [14]. In another study, hepatosteatosis was found concurrently in 27% of the patients with chronic hepatitis B [15].…”

Section: Discussionmentioning

confidence: 99%

The incidence rate of hepatosteatose in virus carriers with inactive Hepatitis B

Demircan¹,

Gözel²,

Denk³

et al. 2014

RusOMJ

View full text Add to dashboard Cite

Objective -The aim of this study is to examine the data retrospectively from patients with inactive HBV whose livers were evaluated by ultrasonography and to investigate hepatosteatosis as well as related parameters in this patient group. Material and Methods -In our study, the data of 134 patients, who have applied to the Internal Disease Polyclinic of Elazığ Çağrı Private Medical Center between January 2010 and August 2013 being diagnosed as carriers for inactive HBV and then performed abdominal ultrasonography, were evaluated retrospectively. Information for each patient was accessed by means of both the internal disease polyclinic in our hospital and patient epicrisis reports. The observed levels of plasma trigliserides, LDL cholesterol, AST, ALT, GGT, and ALP were all recorded. Findings -Out of 134 subjects, 72 were male while 62 were female accounting for 54% and 46%, respectively. The mean age of the patients were found to be 44.8±10.6 years old. Hepatosteatosis was found in 92 patients accounting for 68.7 %. The mean of age in some patients diagnosed with steatosis was found 50.1±7.6 years, while the others without steatosis was 33.2±6.0 years suggesting a significant difference compared to the former (p=0.001). Furthermore, a consistency in difference was also found between these two groups with and without hepatosteatosis in terms of average triglyceride levels (p=0.001). The mean GGT levels were consistently higher in the group with hepotosteatosis (p=0.004). No significant difference was found between these two groups regarding their mean cholesterol levels of AST, ALT, ALP, and LDL. Conclusion -In patients with asymptomatically HBV infection, an increased risk for hepatosteatosis comes along with an increased levels of plasma triglycerides and GGT in the course of aging.

show abstract

Host- and disease-specific factors affecting steatosis in chronic hepatitis C

Cited by 228 publications

References 38 publications

Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral Obesity

Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral Obesity

Steatosis: Co-factor in Other Liver Diseases *

The incidence rate of hepatosteatose in virus carriers with inactive Hepatitis B

Contact Info

Product

Resources

About